Skip to main
LFMD

LifeMD (LFMD) Stock Forecast & Price Target

LifeMD (LFMD) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LifeMD is forecasting increases in revenue and subscribers in the upcoming quarters, driven by a strong demand for their telehealth services. The recent addition of Foundayo and partnership with LillyDirect will expand their offering of branded GLP-1 therapies and potentially drive further growth. While lower guidance for 2026 may cause concern, the company remains confident in their investments and potential for future profitability. Risks include competition and potential challenges with their technology and data sources, while potential upside could come from favorable outcomes in regulatory inquiries and international market performance.

Bears say

LifeMD is facing significant pressure in the second quarter of 2026, with high cost-per-acquisition and increased competition for its weight loss offerings impacting earnings. Despite recent improvements in both CACs and branded GLP-1 pricing, the company's growth in new weight loss members remains relatively low. In addition, risks such as cybersecurity threats and the need to retain key employees may impact the company's ability to sustain its current growth rates. Despite potential growth in other categories such as Women's Health, the company's young, high-growth nature and reliance on third-party partnerships make it a risky investment.

LifeMD (LFMD) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LifeMD (LFMD) Forecast

Analysts have given LifeMD (LFMD) a Strong Buy based on their latest research and market trends.

According to 7 analysts, LifeMD (LFMD) has a Strong Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LifeMD (LFMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.